Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant…

Posted: April 15, 2023 at 12:26 am

NEW YORK and LONDON, April 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the company will host a virtual key opinion leader event on May 22, 2023 at 2 pm ET to discuss the treatment landscape in geographic atrophy (GA) and the potential for long-acting PAS-nomacopan to address significant unmet needs. Akari’s lead asset is investigational nomacopan, a novel bispecific inhibitor of both complement C5 and leukotriene B4 (LTB4). Long-acting PAS-nomacopan is currently in pre-clinical development as a potential treatment for GA.

The rest is here:
Akari Therapeutics to Host Key Opinion Leader Webinar on Geographic Atrophy and the Potential of Long-Acting PAS-Nomacopan to Address Significant...

Related Posts